What is Royalty Pharma's market cap?

Royalty Pharma (RPRX) has a market capitalization of $25.9B and trades on NASDAQ.

What is Royalty Pharma's revenue and profitability?

Royalty Pharma generated $2.4B in trailing twelve-month revenue with net income of $827.3M, representing a net margin of 33.9%. These figures are based on the Q1 2026 filing.

Who are Royalty Pharma's competitors?

Royalty Pharma's key competitors include Ligand Pharmaceuticals Inc., XOMA Royalty Corporation Common Stock, Rigel Pharmaceuticals Inc. (New), and others. These companies compete in similar markets and product categories.

Who does Royalty Pharma partner with?

Royalty Pharma's notable partners include Vertex Pharmaceuticals, GSK, Biogen, and others.

What subsidiaries does Royalty Pharma have?

Royalty Pharma's subsidiaries include Royalty Pharma Holdings Ltd, Royalty Pharma, LLC.

Where is Royalty Pharma headquartered?

Royalty Pharma is headquartered in United States of America and employs approximately 89 people. It has been publicly traded since 2020.

Royalty Pharma

RPRX

Royalty Pharma is the leading buyer of biopharmaceutical royalties and a primary funder of innovation across the life sciences industry.

Market cap

$25.87B+68.8%

Revenue$2.4B+7.8%

Net income$827.3M-24.3%

EPS (diluted)$1.91-22.4%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$925.0MBeat by $43.3M EPS$1.30Beat by $0.08

Read the full report

Next report

Aug 5, 2026 (In 3 weeks)

Revenue estimate$789.5M

EPS estimate$1.27

Financials

Q1 2026

Income statement

See full

Revenue$630.6M+11.0%

Operating income$563.0M+5.4%

Net income$294.7M+23.1%

EPS (diluted)$0.67+21.8%

Balance sheet

See full

Cash & equivalents$586.4M-46.1%

Total debt$9.0B+17.8%

Total equity$9.9B+1.6%

Total assets$19.8B+12.5%

Cash flow

See full

Operating cash flow$718.2M+20.5%

Valuation & ratios

Valuation

See full

Market cap$25.87B+68.8%

Enterprise value$34.26B+50.8%

P/E31.3×+16.3×

P/S10.6×+4.0×

Profitability

See full

Operating margin65.1%-18.9pp

Net margin33.9%-14.4pp

Returns & leverage

See full

Return on equity8.4%-2.7pp

Debt / equity0.9×+0.1×

Current ratio2.7×+1.1×

Competitors

By market cap

Royalty Pharma$25.9B+68.8%

BridgeBio Pharma$15.3B+83.7%

Ionis Pharmaceuticals$14.0B+104%

Ligand Pharmaceuticals$6.3B+185%

Ultragenyx Pharmaceutical$3.4B-9.5%

XOMA Corporation$795.5M+147%

Rigel Pharmaceuticals$794.3M+135%

TherapeuticsMD$22.8M+66.9%

By revenue growth

BridgeBio Pharma+355%

Ligand Pharmaceuticals+51.2%

Rigel Pharmaceuticals+47.6%

Ionis Pharmaceuticals+47.5%

Ultragenyx Pharmaceutical+13.5%

XOMA Corporation+13.2%

Royalty Pharma+7.8%

By net margin

Rigel Pharmaceuticals121.51%+103pp

XOMA Corporation69.63%+76.3pp

Ligand Pharmaceuticals55.95%+129pp

Royalty Pharma33.9%-14.4pp

Ionis Pharmaceuticals-30.9%+33.0pp

Ultragenyx Pharmaceutical-90.92%+2.2pp

BridgeBio Pharma-125.85%+405pp

Profile

Royalty Pharma is the leading buyer of biopharmaceutical royalties and a primary funder of innovation across the life sciences industry. The company acquires interests in the top-line sales of approved and development-stage therapies, providing non-dilutive capital to academic institutions, non-profits, and biotechnology companies. Its business model offers investors diversified exposure to high-growth blockbuster drugs while mitigating the operational risks and costs associated with traditional drug development and commercialization.

Competitive position

The company is the largest player in the biopharmaceutical royalty market, holding a significant market share of large-scale transactions compared to its nearest competitors.

GeographiesGlobal, United States, Europe, China

Customer segmentsBiopharmaceutical Companies, Academic Institutions, Non-profit Research Organizations

Business modelRoyalty Interest, Specialty Finance, Capital Allocation

SuppliersAcademic research institutions, Biotechnology R&D, Clinical trial results, Regulatory approval bodies (FDA/EMA)

CustomersGlobal pharmaceutical marketers, Healthcare payors, Patients

CountryUnited States of America

Listed2020

Employees89.0

CEOPablo Legorreta

SectorHealthcare

IndustryBiotechnology

Websiteroyaltypharma.com

FilingsSEC EDGAR

Ask your AI about Royalty Pharma.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Royalty Pharma's market cap?: Royalty Pharma (RPRX) has a market capitalization of $25.9B and trades on NASDAQ.
What is Royalty Pharma's revenue and profitability?: Royalty Pharma generated $2.4B in trailing twelve-month revenue with net income of $827.3M, representing a net margin of 33.9%. These figures are based on the Q1 2026 filing.
Who are Royalty Pharma's competitors?: Royalty Pharma's key competitors include Ligand Pharmaceuticals Inc., XOMA Royalty Corporation Common Stock, Rigel Pharmaceuticals Inc. (New), and others. These companies compete in similar markets and product categories.
Who does Royalty Pharma partner with?: Royalty Pharma's notable partners include Vertex Pharmaceuticals, GSK, Biogen, and others.
What subsidiaries does Royalty Pharma have?: Royalty Pharma's subsidiaries include Royalty Pharma Holdings Ltd, Royalty Pharma, LLC.
Where is Royalty Pharma headquartered?: Royalty Pharma is headquartered in United States of America and employs approximately 89 people. It has been publicly traded since 2020.